HeliyonCancer BiologyPeer-reviewed journal article
Inhibition of Replication Origins and ATR Synergistically Activates the Innate Immune System in Cancer Cells
K. Doberstein, J. Panther, S. Berlit, B. Tuschy, M. Suetterlin, F. Marme
Abstract
Sufficient numbers of activated replication origins are essential for successful DNA replication. While normal cells load replication origins in abundance to the genome, cancer cells often load fewer origins of replication due to genomic alterations such as CCNE1 amplifications. Here we exploit this feature to sensitize cancer cells to ATR inhibition. We show by using siRNA and small molecules that the inhibition of origin activation as well as the reduction of replication origins itself sensitizes ovarian cancer cell lines against ATR inhibition by inducing genomic instability. We further show that in ovarian cancer cells this combinatorial approach leads to an increased genomic instability which manifests in an increase of micronuclei that consequently activate the innate immune system through the cGAS-STING pathway. Notably, no activation of the innate immune system was observed in immortalized fallopian tube cells. However, overexpression of Cyclin E1 in this model leads to a marked increase in genomic instability and innate immune activation. Here we provide preclinical evidence to increase the therapeutic efficacy of ATR inhibitors. Additionally, this approach could help to activate innate immunity and increase T-cell immune infiltration in tumors, providing a rationale for a combination with immune checkpoint inhibitors.
- organism: human
- assay: bulk RNA-seq
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High levels of DNA replication initiation factors indicate ATR inhibitor sensitivity via excessive origin firing
Audrey Lumeau, Pauline Luise Pfuderer, … Sarah Elizabeth McClelland·bioRxiv·Feb 27, 2025
- Dual genome-wide CRISPR knockout and CRISPR activation screens identify common mechanisms that regulate the resistance to multiple ATR inhibitors
E. M. Schleicher, A. Dhoonmoon, … G.-L. Moldovan·bioRxiv·Apr 8, 2020
- Oxidative Base Damage to Telomeres Sensitizes Cancer Cells to ATR Inhibition
Alex Garbouchian, Natália Cestari Moreno, … Ryan P. Barnes·Communications BiologyPeer-reviewed·Jul 11, 2026
- Short-course but not prolonged treatment with ATR inhibitor AZD6738 integrates with radiotherapy to generate a tumor antigen-specific CD8+ T cell expansion in the periphery
F. P. Vendetti, D. A. Clump, … C. J. Bakkenist·bioRxiv·Apr 11, 2022
- G2-to-G0 cell cycle exit underlies sensitivity to ATR inhibition via the p53-p21-RB1 axis
Celina Sanchez, Carlos A. Origel Marmolejo, … Joshua C. Saldivar·bioRxiv·May 1, 2026
- Fork Slowing and Reversal as an Adaptive Response to Chronic ATR Inhibition
D. Dibitetto, A. Sanchi, … M. B. Smolka·bioRxiv·May 18, 2021